AU2004246800B2 - 2-aminopyrimidine derivatives as Raf kinase inhibitors - Google Patents

2-aminopyrimidine derivatives as Raf kinase inhibitors Download PDF

Info

Publication number
AU2004246800B2
AU2004246800B2 AU2004246800A AU2004246800A AU2004246800B2 AU 2004246800 B2 AU2004246800 B2 AU 2004246800B2 AU 2004246800 A AU2004246800 A AU 2004246800A AU 2004246800 A AU2004246800 A AU 2004246800A AU 2004246800 B2 AU2004246800 B2 AU 2004246800B2
Authority
AU
Australia
Prior art keywords
benzamide
phenyl
trifluoromethyl
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004246800A
Other languages
English (en)
Other versions
AU2004246800A1 (en
Inventor
David Bryant Batt
Timothy Michael Ramsey
Michael Lloyd Sabio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004246800A1 publication Critical patent/AU2004246800A1/en
Application granted granted Critical
Publication of AU2004246800B2 publication Critical patent/AU2004246800B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004246800A 2003-06-13 2004-06-11 2-aminopyrimidine derivatives as Raf kinase inhibitors Ceased AU2004246800B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47870903P 2003-06-13 2003-06-13
US60/478,709 2003-06-13
PCT/EP2004/006317 WO2004110452A1 (en) 2003-06-13 2004-06-11 2-aminopyrimidine derivatives as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2004246800A1 AU2004246800A1 (en) 2004-12-23
AU2004246800B2 true AU2004246800B2 (en) 2008-12-04

Family

ID=33551850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004246800A Ceased AU2004246800B2 (en) 2003-06-13 2004-06-11 2-aminopyrimidine derivatives as Raf kinase inhibitors

Country Status (14)

Country Link
US (1) US20060293340A1 (https=)
EP (1) EP1635835B1 (https=)
JP (1) JP2006527230A (https=)
CN (1) CN1805748B (https=)
AT (1) ATE454152T1 (https=)
AU (1) AU2004246800B2 (https=)
BR (1) BRPI0411365A (https=)
CA (1) CA2529090A1 (https=)
DE (1) DE602004024988D1 (https=)
ES (1) ES2338557T3 (https=)
MX (1) MXPA05013349A (https=)
PL (1) PL1635835T3 (https=)
PT (1) PT1635835E (https=)
WO (1) WO2004110452A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
UA94570C2 (en) * 2004-09-09 2011-05-25 Натко Фарма Лимитед Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1939910A (zh) 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
BRPI0718812A2 (pt) 2006-11-16 2013-12-03 Italiana Sint Spa Processo para a preparação de imatinib e intermediários deste
EP2152688A1 (en) * 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
ES2607794T3 (es) * 2007-06-07 2017-04-04 Intra-Cellular Therapies, Inc. Compuestos heterocíclicos novedosos y usos de los mismos
WO2008153959A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
PE20091561A1 (es) * 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
ES2392482T3 (es) * 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
MX2012005332A (es) * 2009-11-13 2012-10-15 Oscotec Inc Inhibidores de cinasa.
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2569288A2 (en) * 2010-05-11 2013-03-20 Krisani Biosciences (P) Ltd. 4,6-dibenzoylamino-2-methyl-pyrimidine derivatives and their use for the treatment of cancer
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CA2818544A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
WO2016172528A1 (en) * 2015-04-23 2016-10-27 Inhibikase Therapeutics, Inc. Compositions and methods for inhibiting kinases
CN108586439A (zh) * 2018-06-03 2018-09-28 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
CN108864060A (zh) * 2018-06-03 2018-11-23 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
CN108610336A (zh) * 2018-06-03 2018-10-02 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
IL314582A (en) * 2022-02-03 2024-09-01 Nexys Therapeutics Inc Aryl hydrocarbon receptor agonists and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022597A1 (en) * 2000-09-13 2002-03-21 Novartis Ag N-phenyl-2-pyrimidine-amine derivatives
WO2002093164A2 (en) * 2001-05-16 2002-11-21 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2003070173A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2004002963A1 (ja) * 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022597A1 (en) * 2000-09-13 2002-03-21 Novartis Ag N-phenyl-2-pyrimidine-amine derivatives
WO2002093164A2 (en) * 2001-05-16 2002-11-21 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 6(11): 1221-26, 4 June 1996 *

Also Published As

Publication number Publication date
AU2004246800A1 (en) 2004-12-23
CN1805748A (zh) 2006-07-19
ATE454152T1 (de) 2010-01-15
BRPI0411365A (pt) 2006-07-25
PL1635835T3 (pl) 2010-06-30
DE602004024988D1 (de) 2010-02-25
EP1635835B1 (en) 2010-01-06
US20060293340A1 (en) 2006-12-28
CN1805748B (zh) 2010-05-26
WO2004110452A1 (en) 2004-12-23
PT1635835E (pt) 2010-03-17
EP1635835A1 (en) 2006-03-22
JP2006527230A (ja) 2006-11-30
MXPA05013349A (es) 2006-03-09
ES2338557T3 (es) 2010-05-10
CA2529090A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
AU2004246800B2 (en) 2-aminopyrimidine derivatives as Raf kinase inhibitors
US20090069360A1 (en) Organic Compounds
CA2697081C (en) 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors
JP5564045B2 (ja) 二環式キナーゼ阻害剤
EP1254138B1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
KR102216284B1 (ko) Dna-pk 억제제
CA2825367C (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
KR100876055B1 (ko) 신규 피리미딘아미드 유도체 및 그의 용도
US10414769B2 (en) 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
TW202003505A (zh) 甲基修飾酵素之調節劑、其組成物及用途
EP3762392B1 (en) Thienopyridine derivatives and pharmaceutical composition comprising same
CN114072148A (zh) Raf激酶的抑制剂
US20090306107A1 (en) Organic Compounds
JP2003527303A (ja) グリコーゲンシンターゼキナーゼ３のインヒビター
WO2008151183A1 (en) Heterocyclic compounds and uses thereof
US9624218B2 (en) Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
WO2014135028A1 (zh) 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
JPWO2013137371A1 (ja) 新規ピリミジン化合物及びそれらを含有する医薬
CN115785074A (zh) Parp7抑制剂及其用途
US20160137640A1 (en) Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof
CN116096708A (zh) 用作用于疗法的蛋白激酶抑制剂的2-氧代-n-(4-(嘧啶-4-基氧基/硫基)苯基)-1,2-二氢吡啶-3-甲酰胺的衍生物
HK40061750A (en) Inhibitors of raf kinases
KR20030064078A (ko) 6-번 위치에 아미노메틸기가 치환된3-하이드록시크로멘-4-온 구조를 갖는 사이클린 의존키나아제 저해제

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired